[
  {
    "ts": null,
    "headline": "LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal",
    "summary": "Eli Lilly is set to buy Orna Therapeutics for $2.4B to expand in vivo CAR-T and circular RNA capabilities, signaling a long-term push to diversify its pipeline.",
    "url": "https://finnhub.io/api/news?id=79a9714db93496723c0a64fbffd847d94868d221dbf0af3ac386612841db3969",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770739800,
      "headline": "LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal",
      "id": 139033420,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Eli Lilly is set to buy Orna Therapeutics for $2.4B to expand in vivo CAR-T and circular RNA capabilities, signaling a long-term push to diversify its pipeline.",
      "url": "https://finnhub.io/api/news?id=79a9714db93496723c0a64fbffd847d94868d221dbf0af3ac386612841db3969"
    }
  },
  {
    "ts": null,
    "headline": "Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line?",
    "summary": "BMY's legacy drugs see sharp generic erosion in 2026, but Eliquis growth and guidance shape expectations as competition heats up in oncology.",
    "url": "https://finnhub.io/api/news?id=70152b51779bd9a533304b4d0ef9fe5769184f1cd54b14f1fbce71453ee519b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770739560,
      "headline": "Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line?",
      "id": 139033468,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BMY's legacy drugs see sharp generic erosion in 2026, but Eliquis growth and guidance shape expectations as competition heats up in oncology.",
      "url": "https://finnhub.io/api/news?id=70152b51779bd9a533304b4d0ef9fe5769184f1cd54b14f1fbce71453ee519b2"
    }
  },
  {
    "ts": null,
    "headline": "AZN Q4 Earnings Miss Estimates, Stock Up on Robust 2026 Growth Outlook",
    "summary": "AZN misses Q4 EPS and sales estimates, but rallies after projecting mid-to-high single-digit revenue growth and low double-digit EPS growth for 2026.",
    "url": "https://finnhub.io/api/news?id=a9078b6b59958fa25f43c9525f00ff4c6d60ff628499c09f9cc8e2505aec07a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770734520,
      "headline": "AZN Q4 Earnings Miss Estimates, Stock Up on Robust 2026 Growth Outlook",
      "id": 139033469,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "AZN misses Q4 EPS and sales estimates, but rallies after projecting mid-to-high single-digit revenue growth and low double-digit EPS growth for 2026.",
      "url": "https://finnhub.io/api/news?id=a9078b6b59958fa25f43c9525f00ff4c6d60ff628499c09f9cc8e2505aec07a2"
    }
  },
  {
    "ts": null,
    "headline": "Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform",
    "summary": "LONDON, February 10, 2026--Calla Lily Clinical Care, a women’s health-focused medical technology company, and Merck, a leading science and technology company, have entered a strategic collaboration to support the continued development of Callavid®, a novel platform for intravaginal drug delivery. The collaboration represents the first industry partnership for the Callavid technology.",
    "url": "https://finnhub.io/api/news?id=9477d0d2303ef98e0ba0d300bccb556296a1ccc8b21ebfb7ef52c15e93945e29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770716100,
      "headline": "Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform",
      "id": 139027745,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "LONDON, February 10, 2026--Calla Lily Clinical Care, a women’s health-focused medical technology company, and Merck, a leading science and technology company, have entered a strategic collaboration to support the continued development of Callavid®, a novel platform for intravaginal drug delivery. The collaboration represents the first industry partnership for the Callavid technology.",
      "url": "https://finnhub.io/api/news?id=9477d0d2303ef98e0ba0d300bccb556296a1ccc8b21ebfb7ef52c15e93945e29"
    }
  },
  {
    "ts": null,
    "headline": "Merck India hosts 6th Merck-Tagore Award: Honours Professor Dr. Lars-Christian Koch for Promoting Intercultural Exchange between India and Germany",
    "summary": "Merck, a leading science and technology company, in collaboration with Goethe-Institut / Max Mueller Bhavan India, the official cultural institute of the Federal Republic of Germany, presented Professor Dr. Lars-Christian Koch with the prestigious sixth Merck-Tagore Award during a celebratory event held at the Royal Opera House in Mumbai.",
    "url": "https://finnhub.io/api/news?id=966c40018eb9e3eb09dd429a76f76bc9353c81b1bfa586e153ef0f95865dcf2f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770710640,
      "headline": "Merck India hosts 6th Merck-Tagore Award: Honours Professor Dr. Lars-Christian Koch for Promoting Intercultural Exchange between India and Germany",
      "id": 139027746,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck, a leading science and technology company, in collaboration with Goethe-Institut / Max Mueller Bhavan India, the official cultural institute of the Federal Republic of Germany, presented Professor Dr. Lars-Christian Koch with the prestigious sixth Merck-Tagore Award during a celebratory event held at the Royal Opera House in Mumbai.",
      "url": "https://finnhub.io/api/news?id=966c40018eb9e3eb09dd429a76f76bc9353c81b1bfa586e153ef0f95865dcf2f"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences: Buy This Stock For Both Dividend And Growth",
    "summary": "Gilead Sciences: Buy This Stock For Both Dividend And Growth",
    "url": "https://finnhub.io/api/news?id=e81d72ae20afbebf3fb8841caae7adbb69cb25fe0e1e1f62e222e0a30a1acee9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770702333,
      "headline": "Gilead Sciences: Buy This Stock For Both Dividend And Growth",
      "id": 139028076,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e81d72ae20afbebf3fb8841caae7adbb69cb25fe0e1e1f62e222e0a30a1acee9"
    }
  },
  {
    "ts": null,
    "headline": "5 Revealing Analyst Questions From Merck’s Q4 Earnings Call",
    "summary": "Merck’s fourth quarter was marked by continued demand for its oncology and cardiometabolic franchises, as well as the impact of several new product launches and strategic acquisitions. Management attributed growth to ongoing uptake of Keytruda in earlier-stage cancers and to strong animal health results. CEO Robert M. Davis highlighted that “successful new product launches, the advancement of important clinical programs, and the expansion of our respiratory and infectious disease portfolios thro",
    "url": "https://finnhub.io/api/news?id=1e0a7ecd0de668447dc2201168bc9ccbd4261f96fadca2cf6d8350e4822eb22f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770701811,
      "headline": "5 Revealing Analyst Questions From Merck’s Q4 Earnings Call",
      "id": 139031924,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck’s fourth quarter was marked by continued demand for its oncology and cardiometabolic franchises, as well as the impact of several new product launches and strategic acquisitions. Management attributed growth to ongoing uptake of Keytruda in earlier-stage cancers and to strong animal health results. CEO Robert M. Davis highlighted that “successful new product launches, the advancement of important clinical programs, and the expansion of our respiratory and infectious disease portfolios thro",
      "url": "https://finnhub.io/api/news?id=1e0a7ecd0de668447dc2201168bc9ccbd4261f96fadca2cf6d8350e4822eb22f"
    }
  }
]